ERBB2 and breast cancer: For example, for a 50-year-old Caucasian patient with T2N2M1 breast cancer consisting of a moderately differentiated tumor and HR (−)/HER2 (−) accompanied by bone metastasis, the three-year survival rate is estimated to be 49.4% without RT and 63.9% with RT.